Cargando…

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients

Background: Quality of life (QoL) studies in patients with mild to moderate Graves' orbitopathy (GO) are scarce. Methods: The original GO-QoL questionnaire was translated to Portuguese and administered to 323 patients with Graves' disease. The clinically active score (CAS) was used to eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villagelin, Danilo, Romaldini, João, Andrade, Juliana, Santos, Roberto, Milkos, Ana, Teixeira, Patricia Fátima dos Santos, Ward, Laura S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460048/ https://www.ncbi.nlm.nih.gov/pubmed/31024443 http://dx.doi.org/10.3389/fendo.2019.00192

Ejemplares similares

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center
por: Pinto, Wanesa, et al.
Publicado: (2020)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2020)

Immunological Features of Paranasal Sinus Mucosa in Patients with Graves’ Orbitopathy
por: Lu, Yi, et al.
Publicado: (2021)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications
por: Urselli, Francesca, et al.
Publicado: (2019)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study
por: Boutzios, Georgios, et al.
Publicado: (2023)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
por: Wagner, Lilly H., et al.
Publicado: (2022)

High IgG4 serum concentration is associated with active Graves orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2023)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET
por: Ochmann, Anna, et al.
Publicado: (2023)

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy
por: Bartalena, Luigi
Publicado: (2022)

Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy
por: Lin, Miaoli, et al.
Publicado: (2015)

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
por: Oeverhaus, Michael, et al.
Publicado: (2023)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_64edqtvq6imd8brlmkk67eeg94